Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTLANASDAQ:NYMXNASDAQ:OXFDNASDAQ:QTNTNASDAQ:VIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$9.88+5.3%$8.62$5.90▼$28.18$971.61M2.212.93 million shs5.56 million shsNYMXNymox Pharmaceutical$0.34$0.17▼$0.74$18.10M0.6494,622 shs932,700 shsOXFDOxford Immunotec Global$21.99$21.98$8.37▼$23.11$570.90M1.421.10 million shsN/AQTNTQuotient$0.44$0.18▼$105.20$980K2.32437,886 shs5.81 million shsVIVOMeridian Bioscience$33.97$33.70$20.35▼$34.38$1.50B0.23973,737 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics+5.33%+3.24%+41.34%+35.34%-56.03%NYMXNymox Pharmaceutical0.00%0.00%0.00%0.00%0.00%OXFDOxford Immunotec Global0.00%0.00%0.00%0.00%0.00%QTNTQuotient0.00%0.00%0.00%0.00%0.00%VIVOMeridian Bioscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTLAIntellia Therapeutics4.655 of 5 stars4.33.00.04.71.42.50.6NYMXNymox PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AOXFDOxford Immunotec GlobalN/AN/AN/AN/AN/AN/AN/AN/AQTNTQuotientN/AN/AN/AN/AN/AN/AN/AN/AVIVOMeridian BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTLAIntellia Therapeutics 2.65Moderate Buy$33.37237.74% UpsideNYMXNymox Pharmaceutical 0.00N/AN/AN/AOXFDOxford Immunotec Global 0.00N/AN/AN/AQTNTQuotient 0.00N/AN/AN/AVIVOMeridian Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OXFD, VIVO, QTNT, NYMX, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTLAIntellia Therapeutics$57.88M17.68N/AN/A$8.56 per share1.15NYMXNymox PharmaceuticalN/AN/AN/AN/A($0.01) per shareN/AOXFDOxford Immunotec Global$73.71M7.75$0.02 per share1,408.78$8.08 per share2.72QTNTQuotient$38.51M0.00N/AN/A($56.17) per share0.00VIVOMeridian Bioscience$333.02M4.49$1.78 per share19.13$8.41 per share4.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)NYMXNymox Pharmaceutical-$6.58M-$0.04N/AN/AN/AN/A-1,589.50%-117.25%N/AOXFDOxford Immunotec Global-$1.81M-$0.05N/AN/AN/A-30.51%-8.39%-7.63%N/AQTNTQuotient-$125.13M-$53.21N/AN/AN/A-413.55%N/A-88.21%N/AVIVOMeridian Bioscience$42.46M$0.9735.02∞N/A12.70%16.74%13.09%N/ALatest OXFD, VIVO, QTNT, NYMX, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANYMXNymox PharmaceuticalN/AN/AN/AN/AN/AOXFDOxford Immunotec GlobalN/AN/AN/AN/AN/AQTNTQuotientN/AN/AN/AN/AN/AVIVOMeridian BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTLAIntellia TherapeuticsN/A4.904.90NYMXNymox PharmaceuticalN/A0.190.19OXFDOxford Immunotec GlobalN/A15.9614.85QTNTQuotientN/A1.791.36VIVOMeridian Bioscience0.073.632.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTLAIntellia Therapeutics88.77%NYMXNymox Pharmaceutical1.14%OXFDOxford Immunotec Global91.90%QTNTQuotientN/AVIVOMeridian Bioscience89.72%Insider OwnershipCompanyInsider OwnershipNTLAIntellia Therapeutics3.10%NYMXNymox Pharmaceutical54.00%OXFDOxford Immunotec Global4.33%QTNTQuotient10.50%VIVOMeridian Bioscience2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableNYMXNymox Pharmaceutical390.51 million41.64 millionOptionableOXFDOxford Immunotec Global27325.96 millionN/ANot OptionableQTNTQuotient4262.58 million2.31 millionOptionableVIVOMeridian Bioscience70244.01 million43.00 millionOptionableOXFD, VIVO, QTNT, NYMX, and NTLA HeadlinesRecent News About These CompaniesMeridian Bioscience Introduces New Enzyme Stabilization Services for Molecular DiagnosticsApril 24, 2025 | finance.yahoo.comMeridian Bioscience Inc (VIVO)April 10, 2025 | uk.investing.comIndia's smartphone mkt grows 6%, Vivo topsNovember 13, 2024 | rediff.comRMeridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to SustainabilityNovember 7, 2024 | finance.yahoo.comMeridian Bioscience Gets $500K Top Prize in POC Blood Lead Test ChallengeOctober 28, 2024 | 360dx.com3Precision BioSciences Launches First Hepatitis B Gene-Editing TrialOctober 26, 2024 | precisionmedicineonline.comPWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comEditas strengthens in vivo gene therapy strategy via $238M LNP tech pact with GenevantOctober 22, 2024 | fiercebiotech.comFVivo and Arm collaborate on chip technology innovation, launch joint labOctober 21, 2024 | digitimes.comDvivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint LabOctober 18, 2024 | malaysiasun.comMMeridian Growth Legacy MERDXOctober 16, 2024 | morningstar.comMSerán Bioscience snags investment from Bain Capital Life SciencesSeptember 17, 2024 | pehub.comVivo T3 Ultra launch on September 12 – check what’s in store for India marketSeptember 6, 2024 | financialexpress.comFVivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comFast-growing MBX Biosciences raises another $63.5 million in fundingAugust 6, 2024 | ibj.comIMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comGrant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systemsMay 17, 2024 | bioworld.comBBiomerica, Inc. (BMRA)May 11, 2024 | finance.yahoo.comVivo X100s Pro with new Dimensity 9300 Plus chip could be launching soonMarch 24, 2024 | gizmochina.comGVivo V30 Pro review: Flagship-grade imaging system in a slender form factorMarch 13, 2024 | business-standard.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOXFD, VIVO, QTNT, NYMX, and NTLA Company DescriptionsIntellia Therapeutics NASDAQ:NTLA$9.88 +0.50 (+5.33%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$10.01 +0.13 (+1.32%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Nymox Pharmaceutical NASDAQ:NYMXNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.Oxford Immunotec Global NASDAQ:OXFDOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Quotient NASDAQ:QTNTQuotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Meridian Bioscience NASDAQ:VIVOMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
